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This article is the last of a three-part series narrating a brief history of breast cancer that has traced the attempts by 
physicians to understand and conquer this disease 
since antiquity.2,3 The series chronicles the millennia 
during which crude and desperate surgery-only 
measures gave way to an understanding of the 
pathobiology of this hormone-responsive cancer. 
Tolling the knell on Halstedian heroic extirpations 
(1894) was the advent of chemotherapy and 
radiotherapy.4,5 On a historical timescale, the arrival of 
these new therapeutic modalities would be recorded 
as part of modern history. Remarkable insights into 
tumour biology in the last century have been the 
catalyst to the meteoric rise of medical oncology. 
The Dividing Cell can be Kil led
It is ironic that the birth of cancer chemotherapy 
occurred in the lap of chemical war weaponry; the 
fact that nitrogen mustard gas caused profound 
bone marrow depression was instrumental in the 
subsequent notion that it could also annihilate cancer 
cells. Following clinical trials, it received approval 
from the USA Food and Drug Administration for 
the treatment of patients with Hodgkin lymphoma. 
Sidney Farber’s first pioneering triumph in achieving 
partial remission in a case of paediatric leukaemia 
in 1947 by administering aminopterin,6 as well as 
the establishment of the National Cancer Institute 
Clinical Trials Cooperative Group Program in 
1955,7 set in motion a wave of research that would 
strengthen as it gave rise to a new specialty. The 
principles of oncological management changed 
forever and resignation to certain impending death 
was no longer the fate of a patient diagnosed with 
cancer.6 Nascent medical oncologists would face 
struggles with incredulity and disbelief before the field 
would establish itself through clinical trials and 
scientific merit.
The term ‘chemotherapy’ acquired an entirely 
new connotation in the pharmacological lexicon 
as a generic synonym for anti-neoplastic drugs, far 
removed from its 19th century Ehrlichian usage for 
“chemicals against infections”. It was subsequently 
prefixed by the adjective ‘adjuvant’ that promised 
greater success at inducing remission after the tumour 
burden had been reduced by surgical extirpation. The 
first beneficiaries were patients with osteosarcomas 
(treated with methotrexate)8 and colon cancer (treated 
with 5-fluorouracil).9 The landmark trials of Bernard 
Fisher, Chair of the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) in the USA, and of Gianni 
Bonadonna, working in the Istituto Nazionale dei 
Tumori in Milan, Italy, proved that a combination of 
drugs with different mechanisms of action (commonly 
cyclophosphamide, methotrexate and 5-fluorouracil) 
significantly extended survival after the complete 
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To a tissue that’s trying to grow
We hope these experiments show
With steroids phenolic
Don’t get metabolic:
Just grab on, and never let go! 
Limerick on the action of oestrogen on the oestrogen receptor.1
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surgical resection of breast tumours—particularly in 
more advanced cancers.5,10,11
Women presenting with locally advanced 
breast cancer inspired a re-evaluation in the ways 
chemotherapy could be utilised. Could chemotherapy 
shrink an otherwise inoperable tumour, rendering it 
amenable to the knife with clear post-surgical margins? 
This assumption initiated the advent of neoadjuvant 
chemotherapy—another unique first for oncology—
and breast cancer spearheaded its later application 
to other cancers. The ‘downsizing’ of a tumour had 
therefore moved from concept to standard practice.
Today, a wide choice of refined options exist for 
medical oncologists who are now long past the days 
of nitrogen mustard gas, notorious for its toxicity. 
Among the seminal drugs whose place in the anti-
breast cancer armamentarium is secure, a few deserve 
mention. In the early 1970s, doxorubicin derived from 
a strain of Streptomyces formed the corner-stone of 
chemotherapy, acting by the intercalation of DNA 
and interruption of replication.12 Paclitaxel, originally 
sourced from the bark of the Pacific yew tree in 1962, 
was found to disrupt microtubule assembly.13 Thirty 
years after its discovery, it generated excitement as 
a success story in treating ovarian cancer. However, 
it was soon tapped in 1994 for its effectiveness in 
treating the most common cancer in females—that 
of the breast.13 Capecitabine, introduced in 1998, 
acted by blocking DNA synthesis and transcription. It 
became one of the options for advanced or metastatic 
cancer after anthracycline and taxanes and had the 
added benefit of oral administration.6 These are just a 
few of the drugs which are now used to treat breast 
cancer and the list continues to grow! 
Cell Signall ing: Enabling a 
multipronged attack
The hormone responsiveness of breast cancer was 
a concept proposed long before Elwood Jensen’s 
discovery of hormone receptors on breast cancer 
cells in 1967.1,14 Circumstantial evidence existed 
as indicators of this, for instance in the fact that 
young women generally had a more aggressive 
form of the disease and because the removal of 
sources of oestrogen (e.g. via an oopherectomy 
or adrenalectomy) increased survival. Hormone 
receptor-positive tumours, either oestrogen receptors 
(ER) or progesterone receptors (PR), were found to 
be predictive of recurrence in several publications in 
1977.15 This triggered the invention of receptor assays 
and, later on, direct demonstration of the receptors on 
the tumour cells. An arena was opened for targeted 
therapy, which was itself a new pharmacological 
approach that would be emulated in the subsequent 
treatment of other cancers. Tamoxifen, a selective ER 
modifier (SERM), held promise for increased survival 
in receptor-positive tumours and was approved as 
an adjuvant therapy for post-menopausal women in 
1986.16,17 The resultant dramatic changes in cancer 
recurrence and survival established its place in 
breast cancer therapy. Subsequently, a gonadotropin-
releasing hormone analogue (goserelin) and aromatase 
inhibitors (anastrozole, letrozole and exemestane) 
have been shown to improve progression-free survival 
in an adjuvant setting.18
The saga of the Her2 gene (now known as 
Her2/neu)—identified between 1982 and 1984 by 
the collaborative effort of a group of American 
scientists from the Robert A. Weinberg Group at 
the Massachusetts Institute of Technology, Rocke- 
feller University and Harvard University—categorised 
breast cancers as Her2-positive or -negative.19 Multiple 
copies of the gene transcribe excess Her2 receptor 
proteins which causes tumour cells to be more 
responsive to growth signals, thus making the tumour 
more aggressive. The trajectory of medical oncology 
was to see the marriage of four disciplines—genetics, 
immunology, pathology and pharmacology—a success 
story of modern day interdisciplinary integration. A 
therapeutic monoclonal antibody became a viable 
option when research in the 1990s culminated in 
the emergence of targeted therapy in 1998 with the 
production of trastuzumab (an anti-Her2 molecule) 
by Genentech Inc. (Roche Group, San Francisco, 
California, USA).20 Tumour biology had provided yet 
another impetus to cancer therapy. A subset of breast 
cancers which are particularly difficult to treat are 
triple-negative tumours (i.e. expressing neither ER, 
PR or Her2). These are effectively tumours without 
a target! However, a silver lining was found in the 
application of poly-adenosine diphosphate-ribose 
polymerase (PARP)-inhibitors that prevent cancer cells 
from repairing defective DNA and thus makes them 
chemo-sensitive. The last few years have witnessed the 
emergence of newer drugs with diverse claims: these 
may find their place in future historical reviews!
The Genie of Hereditary 
Breast Cancer Genes
Identified in 1994–1995, the tumour suppressor 
genes BRCA1 and BRCA2 provided scientific support 
for the notion of hereditary breast cancer.21,22 Their 
significance lay in the possibility that identification 
could result in closer surveillance for high-risk family 
members and give them the option of a bilateral 
salpingo-oophorectomy or prophylactic bilateral 
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earlier examples of evidence-based medicine in this 
context.27 The concepts which Vincent T. DeVita and 
Bonadonna had postulated in the 1970s were verified 
by the highest levels of evidence in 1992. The role of 
adjuvant chemotherapy and hormone therapy was 
now established beyond a doubt; outcomes would 
improve for women with early and locally advanced 
breast cancer and their outlook would change forever. 
Further refinements by these and other groups, 
including the Breast Cancer International Research 
Group (BCIRG), established the role of anthracyclines 
as obligatory in all groups of patients as well as that 
of taxanes in high-risk groups.28 Today, the concurrent 
or sequential use of anthracyclines and taxanes forms 
the backbone of adjuvant and neoadjuvant treatment 
in breast cancer. 
Similarly, following the seminal meta-analysis 
by the EBCTCG in 1992, adjuvant hormone therapy 
became the standard of care for all women with 
hormone receptor-positive disease, which affects 
approximately 50% of pre-menopausal and 70% of 
post-menopausal women.27 Additional progress by 
the NSABP, EBCTCG and other groups, such as the 
Breast International Group, includes the use of 
aromatase inhibitors in post-menopausal women, 
either as switch therapy or for extended use beyond 
tamoxifen.29 Both strategies have led to an improvement 
in progression-free survival compared to tamoxifen, 
with different but acceptable side-effects. The use of 
the monoclonal antibody trastuzumab, which targets 
Her2/neu oncogene amplification in a metastatic 
setting, became the standard of care in the late 1990s. 
In 2005, four groups working independently (including 
the NSABP, BCIRG and Herceptin Adjuvant group) 
showed an unprecedented improvement in survival in 
the adjuvant setting with the addition of trastuzumab 
as the backbone of combination chemotherapy.30,31 The 
challenge had been transformed into an opportunity. 
Expression of Her2/neu protein on cancer cells was 
no longer fraught with apprehension, but rather with 
determination to improve survival with the use of 
targeted therapy. History had been made and the last 
decade has seen efforts to further improve outcomes 
by optimising the duration of trastuzumab treatment, 
adding another monoclonal antibody or receptor 
tyrosine kinase inhibitor and using antibody-drug 
conjugates.
The role of radiotherapy after mastectomy and 
breast-conserving surgery has also been indisputably 
established as a result of large cooperative group 
trials and meta-analyses. Postoperative radiotherapy 
after mastectomy has been shown to reduce local 
recurrence and improve overall survival even when 
systemic treatment is administered.32 After breast-
mastectomy and the possibility of chemoprevention. 
In 1998, more than a decade after its approval to 
treat hormone receptor-positive cancers, tamoxifen 
provided another opportunity for use—this time in a 
risk-reduction role for such individuals.6 
Personalised Medicine in the 
Century of Genetics
The first year of the 21st century opened with a 
‘tumour-on-a-chip’ mood among breast oncologists 
and geneticists. Multigene arrays have raised the 
possibility of basing tumour prognostication and 
treatment on the genomic fingerprints of breast 
cancer.23 Furthermore, breast cancer classifications 
based on molecular subtypes hold promise for 
personalising medicine.24 Breast cancer is no longer 
considered one disease, but rather a mixture of at 
least four diseases: hormone receptor-positive and 
Her2-negative cancer; hormone receptor-positive 
and Her2-positive cancer; hormone receptor-negative 
and Her2-positive cancer, and triple-negative cancer. 
The targets are based on the response of the tumour 
and therapeutic decisions are made accordingly. The 
Oncotype DX® test (Genomic Health Inc., Redwood 
City, California, USA) and other similar commercial 
kits based on multigene assays have since opened a 
market for the new predictive and personalised practice 
of oncology. These tests allow for risk-stratification 
which obviates the need for cytotoxic chemotherapy 
among a low-risk subset of women with breast cancer.
Clinical Trials and Evidence-
based Medicine: The 
backbone of oncology
With the dubious distinction of being the globally 
leading cancer in women, breast cancer has had 
a unique primacy in the 20th century in terms of 
clinical trials in oncology. Efforts to improve breast 
cancer outcomes launched the process by which large 
cooperative groups used evidence-based medicine to 
establish new standards of care, refining treatments in 
the adjuvant, neoadjuvant and metastatic settings. A 
series of large-scale phase III trials by the NSABP and 
meta-analyses published by the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) are only two 
examples of how breast cancer physicians, surgeons, 
radiotherapists and statisticians have come together 
and paved the way for healthcare professionals dealing 
with other cancers.25,26 
A meta-analysis consisting of 133 studies and 
a total cohort of 75,000 women was one of the 
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conserving surgery, treatment with radiotherapy 
reduces disease recurrence by half and breast cancer-
related mortality by a sixth.33
Renaissance in the Battle 
against Breast Cancer: 
Surgical mutilation tempered
At the beginning of the 20th century, attempts were 
already underway to reduce disfigurement and 
morbidity at the hands of the school of surgery 
promoting bold radical mastectomies. A notable first 
step was the move from radical to total mastectomies 
in 1971.6 In 1975–1976, the use of adjuvant chemo-
therapy provided the adjunct that would drive survival 
rates to heights that surgery alone could never achieve. 
Only six years later, a push to breast conservation 
created a movement for lumpectomies, with the 
added choice of ‘mopping up’ any residual tumor cells 
with radiotherapy. In Italy, Veronesi et al. were one of 
several groups around the world espousing the use of 
limited surgery in combination with radiotherapy.34 
The change from axillary dissection, with its attendant 
morbidity caused by lymphoedema of the ipsilateral 
arm, to sentinel node biopsy in selected groups has 
been referred to previously.2 
better together
Multidisciplinary efforts in the management of 
breast cancer became the norm through insights 
into the growth kinetics and biomodulation of 
tumours. Pathological predictive and prognostic 
factors, especially ER, PR and Her2 expression, 
became invaluable in determining therapeutic 
options.3 Despite its relatively short lifetime, medical 
oncology has achieved its rightful place at the 
heart of multidisciplinary breast cancer treatment, 
dispelling dogma and enabling collaboration. It has 
demonstrated the range of its applications to patient 
care, from prevention to rehabilitation, by remaining 
grounded in evidence, accepting and discarding 
therapies through global trials and combining its own 
tools with the best of those from the disciplines of 
surgery and radiotherapy.
early detection and prevention 
galvanise the ‘cure’ movement
In the last decades of the 20th century, the advent of 
mammographies ran parallel with attempts to catch 
the disease early and ensure a cure. This involved 
monitoring a subsection of women whose strong 
family history demanded surveillance. The adage 
that ‘prevention is better than cure’ was adopted 
in both letter and spirit by breast physicians and 
surgeons. Preventative strategic options include 
chemoprophylaxis, bilateral salpingo-oophorectomies 
and prophylactic mastectomies in BRCA-positive 
women, making headlines when espoused by iconic 
celebrities.35 In addition, the decreasing use of horm-
one replacement therapy has had a role in the overall 
decline of breast cancer. A host of chemoprevention 
options utilising SERMs also exist.36
Lessons from the Foundation 
of Tumour Biology for Medical 
Oncology in Breast Cancer
From the mere decimation of tumour cells using single 
agent or combination chemotherapy to endocrine 
manipulation and targeted therapies, advances in 
breast cancer therapy have successfully anchored 
medical oncology in the terra firma of cancer therapy. 
The rise of this new discipline has been anchored by 
parallel, rapid and translational research in tumour 
biology. This has allowed the emergence of generations 
of drugs, either targeting the global cell cycle or 
specific receptors. As critical information regarding 
breast cancer genes and their interplay emerge, we 
bear witness today to the history of personalised 
medicine in the making. 
Life comes with many challenges. The ones that should 
not scare us are the ones we can take on and take 
control of. Angelina Jolie.35
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